Joyzyme Group Limited (8622) has updated its company information as of 9 February 2026. Incorporated in the Cayman Islands, the company first listed on GEM of The Stock Exchange of Hong Kong on 13 December 2018, with RHB Capital Hong Kong Limited as the sponsor.

Joyzyme Group Limited is a medical device group specializing in the research, development, manufacture, and sale of a wide range of in-vitro diagnostic reagents, as well as auxiliary reproductive supplies and equipment, primarily in the PRC. Substantial shareholders include Anselme Limited and its owner, Dr. Zhou Xunyong, collectively holding 259,520,000 shares (50.35% of total issued shares). The company reports a total of 515,472,000 ordinary shares in issue at a par value of HK$0.01 each.

Executive directors comprise Zhang Yujing, Zhou Xunyong, Zhang Chunguang, and Poon Lai Yin Michael, while the board’s independent non-executive directors include Chow Kwok Fai Joseph, Wang Yachun, and Tsui Wing Tak. The company maintains its principal place of business in both Hong Kong and Shenzhen, with a financial year-end date of 31 December.